
John Andrews
@john_andrews__
Followers
91
Following
1K
Media
14
Statuses
100
π Academic Researcher, @anzgog π‘ Mudgee, NSW π§πΌπ¦πΌπ¦π» Dad of 3, he/him
Wiradjuri Land
Joined June 2019
Without doubt, this was one of the best talks Iβve seen at COSA so far. Absolutely inspiring Kat! Well done! ππΌ.#cosa24 @anzgog.
Come and join me as I share reflections on the role of art in the practice of oncology. Excellent panel. Lots of food for thought. Bonus: it will also be a visual feast. #cosa2024
1
2
8
After nearly 3 years of guessing the same starter word it finally came through! I feel like I can now have fun coming up with random words like everyone else I know who plays Wordle religiously. How lame is my life?! π
0
0
2
Congratulations to @g_auyeung on another significant milestone for IGNITE. Hopefully the first of many more patients with CCNE1 over-expression who may benefit from this targeted treatment approach!.
IGNITE recruitment update π―. The first patient of 32 has been enrolled in cohort 3 for ANZGOG's IGNITE study. IGNITE is ANZGOGβs first platform study with the introduction of the third arm with a new agent. #AdvancingResearchSavingLives.
0
0
7
Honored to co-author this paper regarding patient involvement in the development of international gynaecological cancer clinical trials. Hopefully our recommendations & insights encourage higher rates of patient and carer involvement in ALL oncology trials, not just gynae.
A recent publication, led by a group of gynae oncology professionals from within the GCIG assessed the current level of patient involvement in research development across 26 countries. @john_andrews__. Read more:
1
2
10
Grateful to have coauthored this important analysis looking at patient involvement within GCIGβs research. Hopefully the recommendations will be incorporated into future research undertaken by GCIG after demonstrating the value patient contributions can add to trial outcomes.
PUBLICATION ALERT ππ¨. Patient involvement in research within the Gynecological Cancer InterGroup: A call to action for a systematic approach: Results from a survey. @john_andrews__. ANZGOG publications:
0
0
7
Congrats to the research team at @anzgog for this significant milestone, and to @ProfClareScott for your tenacity and passion for changing outcomes for those affected by rare gynae cancer. Hopefully this will be the first patient of many to benefit from this treatment approach.
ANZGOG's EPOCH study has recruited its first patient at @PeterMacCC π. EPOCH is a Phase II open label international clinical trial, which seeks to improve outcomes in women with tubo-ovarian or uterine carcinosarcoma by providing patients with access to a treatment that offers a
0
0
12
Another ASCO conference done & dusted. I appreciate the time I get to spend with our @anzgog members in not only learning more about the latest treatment pathways & optimal treatment approaches, but also connecting & supporting one another through the development of our research
0
1
13
What a whirlwind the last 3 days have been at the #ANZGOG2023ASM. It was inspirational, collegiate and best of all full of smiles and laughs. Canβt wait to do it again next year. A massive shout out to our whole amazing @anzgog team who enable the research we undertake.
1
5
26
Kicking off the #ANZGOGASM2023 with an insightful session looking at the trials and tribulations of developing your research career. So many valuable lessons and advice being shared by the expert panel as well as those in the audience.@anzgog
0
3
14
Congratulations to all of the ANZGOG members who contributed to our grant ππΌ Now the fun begins as we get things rolling and start recruiting eligible endometrial cancer patients.
Congratulations to the TAPER trial team who have been awarded $1.2m from the Medical Research Future Fund (#MRFF) funding by the @healthgovau π. The TAPER study is a collaboration between @CDNCancerTrials and ANZGOG, and will be led by ANZGOG Director Prof Alison Brand AM in ANZ.
1
1
9
To my @anzgog followers, donβt forget to nominate your fellow members for our Recognition Awards presented at our 2023 ASM. There are five categories to nominate your colleagues and/or collaborators in. We canβt wait to celebrate and showcase our amazing members!.
ANZGOG RECOGNITION AWARDS π. ANZGOG members are encouraged to nominate their colleagues who are working to make a difference for women living with gynaecological cancers. Nominations close on Monday 13 Feb π¨. Find out more:
0
0
3
Another insightful publication from the PHAEDRA trial - a collaborative effort from @anzgog and @TrialsCentre under the leadership of @AntillYoland. Each piece of learning from our trials brings us one step closer to #ImprovingLifeForWomen. Congratulations to my co-authors.
NEW PUBLICATION ππ¨. Results of PD-L1 Analysis of Women Treated with Durvalumab in Advanced Endometrial Carcinoma (PHAEDRA). @john_andrews__ @LindaMileshkin @KristyRobledo. ANZGOG publications:
0
3
6
Congrats on another milestone @g_auyeung. IGNITE is demonstrating how important precision medicine is for #ovariancancer & how this treatment approach benefits the patients participating in the important research we undertake at @anzgog. Itβs an honour to do this alongside you.
TRIAL MILESTONE π―. ANZGOG's IGNITE study has now recruited 75% of its total patient accrual, after @PeterMacCC enrolled the trial's 72nd patient. #ImprovingLifeForWomen #ovariancancer. Learn more about IGNITE in the video below π
1
1
11
Thereβs only 1 week to go until @anzgogβs FFNR closes! Research is the key for gynaecological cancer. If you have any questions or queries relating to your application, please contact me at john.andrews@anzgog.org.au.
ποΈReminder: FUND FOR NEW RESEARCH GRANTS ARE OPEN FOR APPLICATION. π°. ANZGOG has made $200,000 available for its Fund For New Research Grants for pre-clinical, translational or clinical trial gynaecological cancer research projects. A maximum of $100,000 per project.
0
1
2
Was a highlight to see @g_auyeung present his IGNITE poster in person at ASCO. Second only to witnessing how many attendees not only eagerly reviewed the content but also sought insights. Itβs an honour to be a co-author on such important work. @anzgog #ASCO2022.
Gynae posters about to start at #ASCO22 So proud to be presenting interim results of the IGNITE trial, on behalf of our study team. Come find me at Board 394. Looking forward to the poster discussion session later! @BowtellLab @PeterMacRes @anzgog @LindaMileshkin
1
3
22
Congratulations @ProfClareScott on a fantastic achievement for SOLACE2! Many thanks from @anzgog to all of the recruiting and referring clinicians, site staff and trial patients and their families - we couldnβt do this without you!.
ANZGOG's SOLACE2 trial has recruited its 100th participant ππ―. The #ovariancancer study is now only 14 participants away from completing recruitment. @TrialsCentre #ImprovingLifeForWomen
0
1
18
So grateful to be back in Melbourne for #anzgog2022asm. Cannot wait to reconnect with our inspirational world leading clinicians and researchers. Thanks for putting on a stunning first morning, Melbourne. What a picturesque start to the day!.#anzgog #PathwaysToPrecisionCare
0
2
21
Thanks to @wnswlhd for their pop-up clinic in @MudgeeRegion today allowing me to get my three kids vaccinated. Efficiently organised with friendly & engaging staff. This makes going back to school in 3 weeks a little less stressful! #CovidVaccine #RegionalHealth #Mudgee
0
1
5
The #HonourHer2021 campaign brings together Australian artists helping @anzgog and WomenCan raise much needed funds for #GynaeCancer research. Affordable and collectible art for a cause π¨Virtual gallery now open to purchase and online auction starts in 2 wks πΌ.
The #HonourHer2021 campaign is live! π. Each September the campaign, led by ANZGOG's fundraising arm - WomenCan, will bring together Australian artists to raise funds for ANZGOG's pioneering research π¨ . Learn more:
0
0
2